M-A | High-volume disease, T stage 4 show largest docetaxel benefit in prostate cancer

Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials – The Lancet Oncology

Commentaries:

Meta-analysis of the Addition of Docetaxel to ADT in Metastatic Hormone-Sensitive Prostate Cancer – The ASCO Post

Disease Volume and T Stage Affect Docetaxel/ADT Efficacy in Prostate Cancer – Cancer Network

Commentary on Twitter

NEW: A systematic review and meta-analysis of individual patient data from the STOPCAP M1 collaboration aims to obtain up-to-date estimates of the effects of docetaxel in patients with metastatic hormone-sensitive prostate cancer. #pcsmhttps://t.co/7mqXeIXMQ5 pic.twitter.com/A7AmjipnVq

— The Lancet Oncology (@TheLancetOncol) July 5, 2023